Nanoform receives €5m loan from Finnish government to accelerate its nanotechnology
Ella Day | June 20, 2025 | News story | Freelancers, Licensing & business development, Research and Development | Devices, Johnson & Johnson, Nanoform Finland, Oncology, amorphous solid dispersion technology, government loan, nanoparticle medicine, nanotechnology, prostate cancer
Nanoform Finland [Nanoform], a leading nanoparticle medicine company, is pleased to announce that Business Finland has approved a €5m research and development loan to support the clinical development of nanoapalutamide, Nanoform’s nanocrystalline formulation of apalutamide. This loan will drive the company’s programme towards more sustainable and accessible nanocrystalline solutions.
The loan covers up to 50% of the costs associated with the clinical development programme, with 30% granted prior to the project and the remaining amount based on realised costs. The loan period is ten years, five of which are instalment-free.
Nanoform is reformulating Johnson & Johnson’s Erleada (apalutamide), a therapy for prostate cancer. Using the company’s technology platforms, the nanoformulated version allows a higher drug load and smaller tablet size with the intention of improving patient adherence and reducing pill burden.
The programme is part of Nanoform’s broader “small as an ingredient” initiative, aiming to replace conventional amorphous solid dispersion technologies with more sustainable and patient-friendly nanocrystalline solutions.
“We are grateful for Business Finland’s continued support and confidence in our technology and vision,” said Edward Hæggström, CEO of Nanoform. “This funding enables us to further accelerate the clinical validation of our nanoformulation platform and bring a more patient-friendly and sustainable alternative to the market.”
Ella Day
20/6/25
Related Content
Johnson & Johnson commits $2bn to new manufacturing facility in North Carolina, US
Johnson & Johnson has announced a $2bn investment in a new manufacturing facility in Holly …
Johnson & Johnson submits FDA application for Caplyta to prevent schizophrenia relapse
Johnson & Johnson has submitted a supplemental New Drug Application to the US Food and …
Johnson & Johnson seeks EMA approval to accelerate prostate cancer treatment
Johnson & Johnson has submitted an application to the European Medicines Agency for an indication …
